

ASX Announcement

Quarterly Activities Report and Appendix 4C for the three months ended 31 December 2025

Coolum, Australia / 30 January 2026 – Australian research, development and commercialisation company Terragen Holdings Limited (“**Terragen**”) provides an update on key activities across the business for the three month period ended 31 December 2025 and to date (**Quarter**).

Summary

- Ruminant Probiotic assessment announced with Mort & Co Grassdale of >10,000 head.
- Terragen Probiotic[®] for Ruminants (**TPR**) sales in Q2 are up 87% on Q1, after launching in late April 2025
- Elders Pakenham trials deliver the highest estimated yield (8.46 kg/m²), driven by the heaviest average fruit weight (233.4 g) in a commercial tomato glasshouse, using Great Land Plus[®] (**GLP**).
- Total sales impacted by drought and trading conditions in the dairy sector.
- The strategy to utilise the patented strains in companion animals is progressing.
- GLP is found to be compatible with Roundup Ready crops (Roundup Ready crops are genetically engineered to withstand the direct application of glyphosate-based herbicides, specifically Roundup).

Terragen Probiotic[®] for Ruminants for Beef

- **Mort & Co to assess over 10,000 head¹**

Mort & Co at Grassdale feedlot (Australia’s largest single-site beef feedlot) will assess the feedlot and eating quality performance of grain-fed cattle over a 100-day feeding program. Under the guidance of Professor Jane Quinn of Charles Sturt University (**CSU**), over 10,000 head in 20 replicated data sets will enter Grassdale feedlot.

Under the trial, Terragen will develop an automated biological dispenser to be integrated into the current feeding systems at Grassdale, ensuring seamless integration of TPR into a commercial feeding program.

Under CSU guidance, the carcasses will be graded according to Meat Standards Australia² (**MSA**) to determine the carcass value added when TPR is fed at a commercial scale.

The trial aims to replicate the results of the CSU trial at Wagga Wagga³, where carcass value increased by \$57 per carcass when sold through Teys/Cargill.

The trial is a 100-day on-feed trial, with feedlot data anticipated in July/ August 2026, with carcass data anticipated to be available later in September/ October 2026. The full CSU report is then anticipated in December 2026.

¹ ASX Announcement 18th November 2025

² MSA, a programme of Meat & Livestock Australia (**MLA**) was developed by the Australian red meat industry to improve the eating quality consistency of beef and sheepmeat. The system is based on almost 1.7 million consumer taste tests by more than 250,000 consumers from 13 countries and considers all factors that affect eating quality from the paddock to plate.

³ ASX Announcement 17th December 2024

- **Global Market Access**

During the Quarter, Terragen obtained necessary permits from the Canadian Food Inspection Agency (CFIA) to allow TPR to be used for research settings with commercial livestock. The previously announced trial led by Agriculture and Agri-Food Canada, being undertaken at the Lethbridge Research and Development Centre in Alberta was subsequently able to begin animal phases within the Quarter⁴.

Phase 1 of the trial focusing on animal health, intensive digestion and immune parameters was completed in the Quarter in line with expectations, and data analysis is underway. Phase 2 has now commenced, extending the study under replicated commercial feedlot conditions to assess longer-term performance, health and carcass outcomes. The animal Phase 2 of the trial is anticipated to conclude in July 2026, with data analysis and reporting to follow soon after.

The trial is anticipated to generate independent, peer-grade data to support Terragen's North American market entry and regulatory and commercial discussions. Terragen has been in negotiation with a global nutrition company seeking to manufacture and distribute TPR in North America. As at the date of this announcement, no binding or non-binding arrangements have been entered into. Terragen will update the market in the event a binding distribution and manufacturing agreement for North America or any other jurisdictions have been entered into.

Recent organisational changes within the U.S. Food and Drug Administration have resulted in some extension to anticipated market access approval timelines. The Department of Agriculture, Livestock and Food Supply (MAPA) has approved the active strains for use in Brazil, and Terragen is working with consultants to gain final regulatory certification for TPR. Similarly, Terragen is working with Knoell consultants on finalising commercial access to Canada through CFIA.

- **Terragen Probiotic® for Ruminants for Lamb**

As detailed in the quarterly for the three months ended 30 September 2025, TPR has been used for approximately 11,000 head of lamb per day, initially on a trial basis, to the end of December 2025. Terragen has received confirmation for approximately 11,000 doses per day to the end of June 2026.

A further producer-led commercial demonstration is also underway with a 20,000 head lamb feedlot in the Wimmera region of Western Victoria, with interim results anticipated from March 2026.

- **TPR Sales**

The new product, Terragen Probiotic® for Ruminants (TPR) was launched in late April 2025. Sales in Q2 are up 87% on Q1.

- **Terragen Probiotic® for Ruminants – Companion Animals**

Following the successful completion of independent safety and palatability trials⁵, Terragen progressed to pilot-scale manufacturing of the preferred formulation in collaboration with global manufacturer SACCO Systems. All strains have been successfully grown and freeze-dried at

⁴ ASX announcement 18th November 2025

⁵ ASX Announcement 18th November 2025

commercial scale, achieving viable and commercially feasible outcomes. Terragen has now received the necessary permits to import active strains into Australia for commercial manufacturing⁶.

Terragen has been in negotiations with a global companion animal company seeking to place Terragen's canine probiotic in their brand and retail. As at the date of this announcement, no binding or non-binding arrangements have been entered into.

Terragen will update the market in the event a distribution and retailing agreement is entered into.

- **Researching a nitrogen-fixing solution for the global market, through QUT⁷**

Terragen previously announced it has isolated new microbes with nitrogen-fixing, phosphorus-solubilising, and methylotrophic traits with a special focus on free soil and plant nitrogen-fixing bacteria, in collaboration with Queensland University of Technology.

Project Update

Terragen's laboratory research program into potential nitrogen fixing microbial strains which focused on strain identification, functional characterisation and agricultural application established a strong scientific foundation for participation in the Queensland University of Technology and Food Agility CRC collaborative project, *Microbial Solutions for Agricultural Emissions*.

As at 31 December 2025, pot trials assessing two of Terragen's selected strains have demonstrated statistically significant increases in biomass in sorghum, canola and barley. Ongoing work under the project will now seek to replicate these findings across optimised concentrations and strain combinations. This will inform formulation selection for subsequent trials and generate the additional data required to assess commercial feasibility, before recommending optimal formulation(s) to be extended to in-field conditions.

Terragen Biostimulant – Great Land Plus

- **Biostimulant Great Land Plus[®] (GLP) rapid decomposition**

Terragen advised that it has received a purchase order from Mort & Co Fertilisers for the supply of Terragen's biostimulant product (GLP)⁸. Deliveries under the purchase order are expected to occur progressively during the 2026 calendar year.

Based on the purchase order covering the six months to 30 June 2026 and historical ordering patterns, Terragen anticipates that sales of GLP in the third and fourth quarters of FY2026 will increase by approximately 57% on current monthly GLP sales.

Terragen advises that it is currently in discussions with the Australian subsidiary of a global agribusiness regarding the potential distribution of its biostimulant product, GLP. As at the date of this announcement, no binding or non-binding arrangements have been entered into. Terragen will update the market in the event a distribution and retailing agreement is entered into.

⁶ ASX Announcement 18th November 2025

⁷ ASX announcement November 18th 2025

⁸ ASX Announcement 17th November 2025

- **Biostimulant Great Land Plus® Compatibility**⁹

Independent trials conducted by MALDI-ID found that GLP is compatible with Roundup Ready (made by Bayer). Genetically Modified (**GM**) seeds cover 190.4 million hectares per annum globally, upon which Roundup Ready is applied to the crop. GLP can be mixed with Roundup ready allowing growers of GM seed to apply both weed control and a biostimulant

The research confirms that GLP performs well in a mixed system with Round Up Ready® when it's sprayed within a practical working window of six hours, allowing growers to spray weeds and apply a biostimulant in one application.

- **Biostimulant Great Land Plus® Commercial Outcomes**

Glasshouse Tomato Root Drench Trial – Large commercial glasshouse tomatoes, Victoria, December 2025. During the Quarter, Elders Rural Services Pakenham conducted a commercial trial in one of Australia's largest glasshouses, which was managed independently by the grower's agronomist.

The trial found that GLP achieved the highest estimated yield (8.46 kg/m²), driven by the heaviest average fruit weight (233.4 g). Despite lower fruit set per m² than the control, Terragen's larger fruit delivered superior mass per area. Flowering height was lowest for Terragen (more generative balance), supporting earlier truss (early trusses often carry **heavier fruit first**).

- **Biostimulant Great Land Plus® Commercial sites**

Terragen, MALDI ID and Nutrien Waroona Rural Services, Western Australia summer field trial program, December 2025

The trial is to be undertaken at demonstration sites to understand the case for the use of GLP for summer cropping on irrigated paddocks in Waroona, regional Western Australia, measuring the effect of GLP compared to control on yield and soil microbial populations. The results of the trial will be published in June 2026.

The cropping systems to be assessed as part of the trial are.

- Sorghum on 45ha pivot – 20ha treated
- Maize on 40ha pivot – 20ha treated (2 timings)
- Perennial Pasture on 11ha pivot – 5ha treated
- Super Sudan Sorghum on 11ha pivot – 5ha treated

Summit Ag Consulting managed a farmer user demonstration, Cotton, Hay, New South Wales.

In collaboration with Summit Ag Consulting, a trial is to be undertaken at sites to understand the case for the use of GLP on Cotton sown late under abiotic stress conditions, with key measures including plant height, nodes, flowers and yield.

The results of the trial will be published after harvest in May 2026.

⁹ ASX Announcement 18th November 2025

Ravensworth Agriculture Irrigated Maize Silage, Hay New South Wales¹⁰

This commercial demonstration is being undertaken in order to understand the case for the use of GLP, and its enhancement on maize silage crop health with a standard fertiliser program. The site for the demonstration utilises Laconik remote sensing software to replicate 12 times across 4 treatments, for independent data. Key measures include crop health, yield and feed quality.

Trail results will be published after the harvest in June 2026.

Financial highlights

As at 31 December 2025, Terragen had \$2.8m of cash reserves, a decrease of approximately \$0.2 m from 30 September 2025. Cash receipts for the Quarter were 256% higher than the prior Quarter due to timing of receipts from the prior quarter's sales and seasonal demand fluctuations. Research and development costs of \$91k are more in line with anticipated quarterly expenditure. Product manufacturing and operating costs of \$244k are more in line with anticipated quarterly expenditure, in the prior quarter these costs included \$364k of bulk raw material purchases. In December 2025 the Company received \$989k from the R&D Tax Incentive. At 31 December 2025, the Group held a term deposit of \$105k which is restricted for the use of bank guarantees and has been reclassified in the current quarter.

Payments to related parties

In item 6 of the Appendix 4C cash flow report for the Quarter, payments to Related Parties of \$123k. This comprises payments made to Company Directors (executive and non-executive) in the form of Directors' fees and salaries.

About Terragen

Terragen specialises in the development of biological products that improve animal and plant health for use in agriculture. Our proprietary research has led to the creation of innovative products that improve livestock and crop yields and deliver positive environmental outcomes, helping to decarbonise agriculture.

Currently, Terragen has two products available for sale across Australia and New Zealand, Ruminant Probiotic and Great Land Plus (GLP). Ruminant Probiotic is a feed supplement that increases average daily weight gain and reduces methane production. GLP is a plant bio-stimulant targeted for use in cropping that reduces reliance on chemical-based fertilisers, decreasing scope emissions. GLP also increases crop yields and soil organic carbon levels.

For further information, please contact:

Terragen Holdings Limited	Authorisation and Additional Information
Mike Barry Chair Mikeb@terrigen.com.au	This announcement was authorised by the Board of Directors of Terragen Holdings Limited
Richard Norton Managing Director and CEO Richardn@terrigen.com.au	

¹⁰ ASX announcement November 18th 2025

Attachment 1

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

TERRAGEN HOLDINGS LIMITED

ABN

36 073 892 636

Quarter ended ("current quarter")

31 December 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	428	595
1.2 Payments for		
(a) research and development	(91)	(190)
(b) product manufacturing and operating costs	(244)	(748)
(c) advertising and marketing	(125)	(215)
(d) leased assets	-	-
(e) staff costs	(586)	(1,487)
(f) administration and corporate costs	(255)	(497)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	32	43
1.5 Interest and other costs of finance paid	(31)	(63)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives (FY24 R&D tax benefits)	989	989
1.8 Other (annual commissions paid to customers)	-	-
1.9 Net cash from / (used in) operating activities	115	(1,575)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(7)	(37)
	(d) investments	-	-
	(e) intellectual property	(12)	(21)
	(f) other non-current assets	(105)	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(124)	(58)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(132)	(246)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	(132)	(246)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,958	4,805
4.2	Net cash from / (used in) operating activities (item 1.9 above)	115	(1,575)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(124)	(58)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(132)	(246)
4.5	Effect of movement in exchange rates on cash held	(1)	(6)
4.6	Cash and cash equivalents at end of period	2,816	2,921

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1 Bank balances	2,116	2,853
5.2 Call deposits	700	104
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)	2,816	2,957

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

123

-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

Represent payments made to Company Directors (executive and non-executive) in the form of Directors fees and Salaries.

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	390	390
7.2 Credit standby arrangements	-	-
7.3 Other – finance lease liabilities	96	96
7.4 Total financing facilities	486	486

7.5 **Unused financing facilities available at quarter end** Nil

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

Financing facilities represent liabilities under leasing and hire purchase arrangements and annual insurance premium funding. These facilities are secured against assets with a written down book value of approximately \$483k as at 31 December 2025.
All financing arrangements have a maturity date of less than 4 years.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	115
8.2 Cash and cash equivalents at quarter end (Item 4.6)	2,921
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	2,921
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **30 January 2026**

Authorised by: **The Board of Directors of Terragen Holdings Limited**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.